Search results for " COVID-19 vaccines"

showing 10 items of 15 documents

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

2022

International audience; Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are essential for ending the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand alone. We describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized prefusion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein named GRAd-COV2. We assessed the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group…

2019-20 coronavirus outbreakCOVID-19 VaccinesSettore BIO/06Coronavirus disease 2019 (COVID-19)COVID-19 VaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GorillaAdenoviridaeAdenovirus Vaccinesbiology.animalPandemicAnimalsHumansMedicineMESH: COVID-19MESH: AnimalsMESH: SARS-CoV-2AgedMESH: Adenovirus VaccinesMESH: AgedGorilla gorilla[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: HumansbiologyAnimalSARS-CoV-2business.industryMESH: Gorilla gorillaCOVID-19MESH: AdenoviridaeGeneral MedicineVirologyAdenovirus VaccineMESH: COVID-19 Vaccinesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHuman
researchProduct

Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.

2021

Background: Previous research has shown that young adults are more hesitant/resistant to COVID-19 vaccine uptake than older age groups, although the factors underlying this tendency are still under debate. The current study aimed to identify the sociodemographic and psychological correlates of vaccine hesitancy and resistance among young adults (18–40 years) during the nationwide COVID-19 vaccination campaign in Italy, the first country after China being hit by the pandemic and which suffered a large number of fatalities. Methods: This is a cross-sectional, web-based study conducted in Italy using an ISO-certified international survey company (respondi.com). Data were collected on 1200 part…

AdultCOVID-19 VaccinesGeneral VeterinaryGeneral Immunology and MicrobiologySARS-CoV-2VaccinationPublic Health Environmental and Occupational HealthCOVID-19; Italy; Psychological correlates; Vaccine hesitancy; Young adults; Adult; Aged; Cross-Sectional Studies; Humans; SARS-CoV-2; Vaccination; Vaccination Hesitancy; Young Adult; COVID-19; COVID-19 VaccinesCOVID-19Settore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'EducazioneYoung AdultInfectious DiseasesCross-Sectional StudiesItalyMolecular MedicinePsychological correlatesHumansVaccination HesitancySettore M-PSI/05 - Psicologia SocialeVaccine hesitancyYoung adultsAgedVaccine
researchProduct

Reply to “Caution in underrepresentation of older adults in clinical trials on COVID-19 vaccines”

2021

We would like to thank Chen et al. for their comments on our recently published paper in Ageing Research Reviews (Veronese et al., 2021). In this reply we would like to answer to the points raised in their letter. Regarding the first question, we decided to run our search only in PubMed/Medline and ClinicalTrials.gov since the phase II-III randomized controlled trials of SARS-CoV 2 vaccines, considering the urgency for interventions to ameliorate the pandemic situation, received a great deal of interest. Therefore, they were usually published in high impact factor journals, reported in PubMed, and their protocols were usually reported in clinicaltrials.gov. However, following the suggestion…

Agingmedicine.medical_specialtyCOVID-19 Vaccinesmedia_common.quotation_subjectMEDLINEPsychological interventionBiochemistryArticlelaw.inventionRandomized controlled triallawAged Humans SARS-CoV-2 COVID-19 COVID-19 VaccinesmedicineHumansQuality (business)Molecular Biologymedia_commonAgedProtocol (science)Vaccinesbusiness.industrySARS-CoV-2COVID-19Clinical trialNeurologyPublishingFamily medicineParagraphbusinessPsychologyBiotechnologyAged; Humans; SARS-CoV-2; COVID-19; COVID-19 Vaccines
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct

Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM …

2020

Abstract Objectives To evaluate the strength of association between maternal and pregnancy characteristics and the risk of adverse perinatal outcomes in pregnancies with laboratory confirmed COVID-19. Methods Secondary analysis of a multinational, cohort study on all consecutive pregnant women with laboratory-confirmed COVID-19 from February 1, 2020 to April 30, 2020 from 73 centers from 22 different countries. A confirmed case of COVID-19 was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The primary outcome was a composite adverse fetal outcome, defined as the presence of either abortion (pre…

COVID-19 VaccineInfectious Disease TransmissionPerinatal DeathAbortionClinical Laboratory TechniqueMiscarriageCohort Studies0302 clinical medicineCOVID-19 TestingPregnancyRisk Factors3123 Gynaecology and paediatricsSecondary analysisPerinatal medicineAbortion SpontaneouMedicineVertical030212 general & internal medicineViralPregnancy Complications Infectiouscoronavirus; perinatal morbidity; perinatal mortality; covid-19Coronavirus; perinatal morbidity; perinatal mortality; Abortion Spontaneous; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Cohort Studies; Coronavirus Infections; Female; Gestational Age; Humans; Infant Newborn; Infant Premature; Infectious Disease Transmission Vertical; Pandemics; Pneumonia Viral; Pregnancy; Pregnancy Complications Infectious; Pregnancy Outcome; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; SARS-CoV-2; Betacoronavirus; Fetal Death; Perinatal Deathperinatal morbidity030219 obstetrics & reproductive medicineObstetricsReverse Transcriptase Polymerase Chain ReactionInfectiousPregnancy OutcomeGestational ageObstetrics and Gynecology3. Good healthSettore MED/40perinatal mortalityGestationFemaleCoronavirus InfectionsInfant PrematureHumanmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)CoronaviruPneumonia ViralSocio-culturaleGestational AgeIntrauterine deviceCoronavirus; perinatal morbidity; perinatal mortality03 medical and health sciencesBetacoronavirusPARVOVIRUS B19 INFECTIONCoronavirus perinatal morbidity perinatal mortalityHumansAdverse effectPrematurePandemicsFetal DeathPregnancyFetusBetacoronaviruPandemicCoronavirus Infectionbusiness.industryClinical Laboratory TechniquesSARS-CoV-2Risk FactorSpontaneousMORTALITYInfant NewbornAbortionCOVID-19InfantOdds ratioPneumoniamedicine.diseaseNewbornInfectious Disease Transmission VerticalAbortion SpontaneousPregnancy ComplicationsCoronavirusPediatrics Perinatology and Child HealthPregnancy Complications InfectiouCohort StudiebusinessCoronavirus; perinatal mortality; perinatal morbidityJournal of perinatal medicine
researchProduct

Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study

2022

To date there has been limited head-to-head evaluation of immune responses to different types of COVID-19 vaccines. A real-world population-based longitudinal study was designed with the aim to define the magnitude and duration of immunity induced by each of four different COVID-19 vaccines available in Italy at the time of this study. Overall, 2497 individuals were enrolled at time of their first vaccination (T0). Vaccine-specific antibody responses induced over time by Comirnaty, Spikevax, Vaxzevria, Janssen Ad26.COV2.S and heterologous vaccination were compared up to six months after immunization. On a subset of Comirnaty vaccinees, serology data were correlated with the ability to neutr…

COVID-19 VaccinesAd26COVS1vaccines.SARS-CoV-2ImmunologyCOVID-19serologyViral VaccinesvaccinesHumansB-cell memory; COVID-19; cell-mediated immunity; serology; vaccinescell-mediated immunityImmunology and AllergyB-CELL MEMORY COVID-19 CELL-MEDIATED IMMUNITY SEROLOGY VACCINESB-cell memoryLongitudinal StudiesB-cell memory; COVID-19; cell-mediated immunity; serology; vaccines; Humans; Aged; COVID-19 Vaccines; Longitudinal Studies; Ad26COVS1; SARS-CoV-2; COVID-19; Viral VaccinesAgedFrontiers in Immunology
researchProduct

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the …

2021

High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients’ needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: ‘how can we deal with COVID-19 infection in cancer patients?’ In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health car…

Cancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)FAVO Federazione delle Associazioni di Volontariato in OncologiaReviewWHO World Health OrganizationCIPOMO Italian College of Primary Hospital Medical OncologistsSICO Società Italiana di Chirurgia OncologicaMedicalNeoplasmsHealth carePandemicMedicinecancerCentral Venous CathetersHumansFNOPI Federazione Nazionale Ordini Professioni InfermieristicheSocieties MedicalAIRO Associazione Italiana Radioterapia e Oncologia clinicaOncologistsClinical Trials as Topictreatmentbusiness.industryHigh mortalityAIOM Associazione Italiana di Oncologia medicaCancerNeoplasms therapyAIOM; cancer; COVID-19; treatment; vaccination; Central Venous Catheters; Clinical Trials as Topic; Humans; Influenza Vaccines; Oncologists; Practice Guidelines as Topic; COVID-19; COVID-19 Vaccines; Neoplasms; Societies MedicalCOVID-19medicine.diseasevaccinationCOMU College of University Medical OncologistsOncologyInfluenza VaccinesFamily medicineFOCE ConFederazione degli Oncologi Cardiologi e EmatologiPractice Guidelines as TopicESMO European Society for Medical OncologybusinessSocietiesSIPO Società Italiana di Psico-OncologiaAIOMESMO open
researchProduct

Determinants of COVID-19 Vaccine Rollouts and Their Effects on Health Outcomes

2022

Background Vaccination against the coronavirus disease (SARS-CoV-2) is understood to be the key way out of the COVID-19 pandemic. Limited evidence exists on the determinants of vaccine rollouts and their health effects at the country level. Objective Examine the determinants of COVID-19 vaccine rollouts and their effects on health outcomes. Methods Ordinary least squares regressions with standard errors clustered at the country level for Cross-section and Panel daily data of vaccinations and various health outcomes (new COVID-19 cases, fatalities, intensive care unit (ICU) admissions) for an unbalanced sample of about 200 countries during the period 16 December 2020 to 20 June 2021. Results…

Economics and Econometricsand (iii) COVID-19 cases in neighboring countries can lead to an increase in a country's domestic caseload and hamper efforts in taming its own local outbreak. Conclusions: By providing an early broad overview of the quantitative empirical estimates of the determinants of vaccine rollouts and the effects of COVID-19 vaccines our paper can help policymakers make informed decisions about local and global distributions of vaccines as well as related policy tools such as containment measure.Coronavirus disease 2019 (COVID-19)business.industryHealth PolicyNational accountsOutbreakGeneral Medicine(ii) vaccine deployment significantly reduces new COVID-19 infections Intensive Care Unit (ICU) admissions and fatalities and is more effective when coupled with stringent containment measures or when a country is experiencing a large outbreakVaccination against the coronavirus disease (SARS-CoV-2) is understood to be the key way out of the COVID-19 pandemic. Limited evidence exists on the determinants of vaccine rollouts and their health effects at the country level. Objective: Examine the determinants of COVID-19 vaccine rollouts and their effects on health outcomes. Methods: Ordinary least squares regressions with standard errors clustered at the country level for Cross-section and Panel daily data of vaccinations and various health outcomes (new COVID-19 cases fatalities intensive care unit (ICU) admissions) for an unbalanced sample of about 200 countries during the period 16 December 2020 to 20 June 2021. Results: We find evidence that: (i) early vaccine procurement domestic production of vaccines the severity of the pandemic a country's health infrastructure and vaccine acceptance are significant determinants of the speed of vaccination rolloutHealth outcomesIntensive care unitlaw.inventionVaccinationProcurementlawEnvironmental healthPandemicGeneral Earth and Planetary SciencesMedicinebusinessGeneral Environmental ScienceIMF Working Papers
researchProduct

Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study

2022

Background: The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy. Methods: A multicentric and web-based cross-sectional survey was conducted among patients affected by neuropathy from part of South Italy. Results: Out of 285 responders, n = 268 were included in the final analysis and n = 258 of them (96.3%) were fully vaccinated. Adherence to vaccination was higher in patients with hereditary neuropathies compared to others, while it was lower in …

General NeuroscienceSARS-CoV-2 infectionCIDP COVID-19 vaccines SARS-CoV-2 infection autoimmune neuropathy hereditary neuropathy neuropathy reactogenicity vaccine hesitancy vaccine safetyreactogenicityvaccine hesitancySARS-CoV-2 infection; COVID-19 vaccines; reactogenicity; vaccine safety; vaccine hesitancy; neuropathy; autoimmune neuropathy; hereditary neuropathy; CIDPneuropathyvaccine safetyCIDPhereditary neuropathyCOVID-19 vaccineautoimmune neuropathy
researchProduct

Prevalence of unwillingness and uncertainty to vaccinate against COVID-19 in older people: A systematic review and meta-analysis.

2021

The coronavirus disease 2019 (COVID-19) has been shown to have more severe health outcomes in older people specifically in relation to mortality and disability. Vaccination seems to be efficacious and safe for preventing the negative consequences of COVID-19, but vaccine hesitancy seems to be high in older adults. We therefore aimed to investigate the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in older people and the factors that can be associated with the unwillingness to vaccinate. For this work, we searched several databases until 18th June 2021 for studies reporting the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in pe…

Low incomeAgingCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ReviewHealth outcomesBiochemistryolder adultvaccinePrevalenceMedicineHumansMolecular Biologyolder adultsAgedbusiness.industrySARS-CoV-2VaccinationUncertaintyCOVID-19Odds ratioConfidence intervalVaccinationCross-Sectional StudiesNeurologyMeta-analysisCOVID-19; hesitancy; older adults; vaccine; Aged; Cross-Sectional Studies; Humans; Prevalence; SARS-CoV-2; Uncertainty; Vaccination; COVID-19; COVID-19 VaccineshesitancyOlder peoplebusinessBiotechnologyDemographyAgeing research reviews
researchProduct